ACADIA Pharmaceuticals Inc. (ACAD) Earnings History
Profitable26 years of earnings data (2000–2025) · Positive TTM net income
Loading earnings history...
ACADIA Pharmaceuticals Inc. (ACAD) Earnings Overview
As of June 22, 2026, ACADIA Pharmaceuticals Inc. (ACAD) reported trailing twelve-month net income of $376M, reflecting +68.4% year-over-year growth. The company earned $2.18 per diluted share over the past four quarters, with a net profit margin of 36.5%.
Looking at the long-term picture, ACAD's historical earnings data spans multiple years. The company achieved its highest annual net income of $391M in fiscal 2025, representing a new all-time high.
ACADIA Pharmaceuticals Inc. maintains industry-leading profitability with a gross margin of 91.7%, operating margin of 9.8%, and net margin of 36.5%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including INVA ($504M net income, 63.8% margin), AXSM (-$188M net income, -28.7% margin), INTR ($1.42B net income, 8.8% margin), ACAD has room to improve margins relative to the peer group. Compare ACAD vs INVA →
ACAD Earnings vs Peers
Earnings metrics vs comparable public companies
ACAD Historical Earnings Data (2000–2025)
25 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $391M | +72.7% | $105M | $2.29 | 36.5% | 9.8% |
| 2024 | $226M | +469.5% | $231M | $1.36 | 23.6% | 24.1% |
| 2023 | -$61M | +71.6% | -$73M | $-0.37 | -8.4% | -10.1% |
| 2022 | -$216M | -28.7% | -$224M | $-1.34 | -41.8% | -43.2% |
| 2021 | -$168M | +40.4% | -$170M | $-1.05 | -34.7% | -35.2% |
| 2020 | -$282M | -19.7% | -$287M | $-1.79 | -63.7% | -64.9% |
| 2019 | -$235M | +4.1% | -$247M | $-1.60 | -69.4% | -72.7% |
| 2018 | -$245M | +15.3% | -$247M | $-1.94 | -109.6% | -110.6% |
| 2017 | -$289M | -6.6% | -$292M | $-2.36 | -231.7% | -234.1% |
| 2016 | -$271M | -65.0% | -$273M | $-2.34 | -1565.9% | -1574.1% |
| 2015 | -$164M | -77.8% | -$165M | $-1.63 | -269578.7% | -269855.7% |
| 2014 | -$92M | -143.7% | -$93M | $-0.95 | -77062.5% | -77691.7% |
| 2013 | -$38M | -82.0% | -$38M | $-0.44 | -3314.2% | -3344.7% |
| 2012 | -$21M | +8.4% | -$21M | $-0.38 | -424.9% | -425.6% |
| 2011 | -$23M | -250.4% | -$23M | $-0.44 | -1101.4% | -1105.6% |
| 2010 | $15M | +133.5% | $15M | $0.39 | 35.9% | 35.8% |
| 2009 | -$45M | +29.7% | -$45M | $-1.20 | -705.5% | -710.5% |
| 2008 | -$64M | -13.9% | -$67M | $-1.73 | -4040.5% | -4212.5% |
| 2007 | -$56M | -25.2% | -$63M | $-1.60 | -746.4% | -829.3% |
| 2006 | -$45M | -32.0% | -$49M | $-1.61 | -553.9% | -603.1% |
| 2005 | -$34M | -31.7% | -$36M | $-1.55 | -311.6% | -326.8% |
| 2004 | -$26M | -83.9% | -$26M | $-2.50 | -562.9% | -566.8% |
| 2003 | -$14M | -9.5% | -$14M | $-1.24 | -191.0% | -186.2% |
| 2002 | -$13M | -26.2% | -$13M | $-8.86 | -205.1% | -201.2% |
| 2000 | -$10M | - | -$11M | $-9.53 | -236.4% | -261.3% |
Download Data
Export ACAD earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
26+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ACAD — Frequently Asked Questions
Quick answers to the most common questions about buying ACAD stock.
What is ACAD earnings per share (EPS)?
ACAD trailing twelve-month (TTM) diluted EPS is $2.18, reflecting +68.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2000 to 2025 is available in the table on this page.
What is ACADIA Pharmaceuticals Inc.'s net income?
ACADIA Pharmaceuticals Inc. (ACAD) trailing twelve-month net income is $376M as of 2025. Earnings grew +68.4% year-over-year. ACADIA Pharmaceuticals Inc. has been profitable for 2 consecutive years.
Is ACAD profitable?
Yes, ACAD is profitable with a TTM net income of $376M and a net profit margin of +36.5%. ACADIA Pharmaceuticals Inc. has generated profits for 2 consecutive years.
What is ACAD's earnings growth rate?
ACAD compound annual EPS growth rates (CAGR): 1-Year: +68.4%, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2000 to 2025.
What are ACAD's profit margins?
ACADIA Pharmaceuticals Inc. net profit margin is +36.5%, operating margin is +9.8%, and gross margin is +91.7%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +39.9%.
Is ACAD growing earnings?
Yes, ACAD earnings are accelerating — EPS growth of +68.4% exceeds the 5-year CAGR of N/A. TTM net income reached $376M. Earnings momentum is strengthening.
What was ACAD's best earnings year?
ACADIA Pharmaceuticals Inc.'s highest annual net income on record is $391M, achieved in fiscal year 2025. Earnings history on this page spans 2000 to 2025 and includes all annual and quarterly figures.
What were ACAD's earnings last quarter?
ACAD's most recent reported quarter was Q1 2026. Net income was $4M with diluted EPS of $0.02. For a full breakdown of all quarters, see the quarterly earnings table on this page.